Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Status:
Recruiting
Trial end date:
2030-09-30
Target enrollment:
Participant gender:
Summary
A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo
in combination with investigator's choice of chemotherapy in participants with BTC after
surgical resection with curative intent.